Scholarlink

Background <p>When bladder cancer recurs after bacillus Calmette–Guérin (BCG) for high-risk non-muscle-invasive disease, after trimodal therapy (TMT), or after other bladder-preserving therapy for muscle-invasive disease, patients face time-sensitive decisions that determine whether cure remains achievable. Treating physicians must guide these choices by balancing oncologic safety with quality of life, comorbidities, and patient preferences.</p> Methods <p>We reviewed 2024–2025 guidelines from the American Urological Association/Society of Urologic Oncology (AUA/SUO), National Comprehensive Cancer Network (NCCN), and European Association of Urology (EAU), while incorporating pivotal trials and recent drug approvals. Emphasis was placed on translating recommendations into practical decision-making for clinicians and patients.</p> Results <p>For post-BCG recurrence, early radical cystectomy (RC) offers the highest chance of cure for medically fit patients and is recommended throughout all three guidelines. When surgery is not possible or declined, bladder-sparing therapies, including four recently US Food and Drug Administration (FDA)-approved drugs, can be considered with strict surveillance. In post-TMT recurrence, RC is standard for invasive relapse, with bladder preservation reserved for select noninvasive cases. In both settings, optimal outcomes require timely workup, presentation of all viable options, and coordination of multidisciplinary input with a strong emphasis on close surveillance and follow-up.</p> Conclusions <p>Management of bladder cancer recurrence is optimized when therapy aligns with patient goals while safeguarding oncologic outcomes. Regardless of the path chosen, early engagement of a multidisciplinary team and shared decision-making are essential to delivering the best possible care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Can Aydogdu,
  • Sean T. McSweeney,
  • Vignesh T. Packiam,
  • Laura Bukavina

摘要

Background

When bladder cancer recurs after bacillus Calmette–Guérin (BCG) for high-risk non-muscle-invasive disease, after trimodal therapy (TMT), or after other bladder-preserving therapy for muscle-invasive disease, patients face time-sensitive decisions that determine whether cure remains achievable. Treating physicians must guide these choices by balancing oncologic safety with quality of life, comorbidities, and patient preferences.

Methods

We reviewed 2024–2025 guidelines from the American Urological Association/Society of Urologic Oncology (AUA/SUO), National Comprehensive Cancer Network (NCCN), and European Association of Urology (EAU), while incorporating pivotal trials and recent drug approvals. Emphasis was placed on translating recommendations into practical decision-making for clinicians and patients.

Results

For post-BCG recurrence, early radical cystectomy (RC) offers the highest chance of cure for medically fit patients and is recommended throughout all three guidelines. When surgery is not possible or declined, bladder-sparing therapies, including four recently US Food and Drug Administration (FDA)-approved drugs, can be considered with strict surveillance. In post-TMT recurrence, RC is standard for invasive relapse, with bladder preservation reserved for select noninvasive cases. In both settings, optimal outcomes require timely workup, presentation of all viable options, and coordination of multidisciplinary input with a strong emphasis on close surveillance and follow-up.

Conclusions

Management of bladder cancer recurrence is optimized when therapy aligns with patient goals while safeguarding oncologic outcomes. Regardless of the path chosen, early engagement of a multidisciplinary team and shared decision-making are essential to delivering the best possible care.